Molecular pathogenesis of human hepatocellular carcinoma

Toxicology

Volumn 181-182, Issue , 2002, Pages 43-47

  Wang, Xin Wei ^a   Hussain, S Perwez ^a   Huo, Teh Ia ^a   Wu, Chuan Ging ^a   Forgues, Marshonna ^a   Hofseth, Lorne J ^a   Brechot, Christian ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Institut Necker   (France)

Author keywords

cDNA microarray; HBx; Hepatitis B virus; Hepatocellular carcinoma; Oxyradical overload diseases; p53

Indexed keywords

NITROGEN; OXYGEN; PROTEIN P53;

APOPTOSIS; CARCINOGENESIS; CHRONIC INFLAMMATION; DNA MICROARRAY; GENE; GENE MUTATION; HBX GENE; HEMOCHROMATOSIS; HEPATITIS B VIRUS; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; ONCOGENE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; RISK FACTOR; TUMOR SUPPRESSOR GENE; VIRUS HEPATITIS; WILSON DISEASE;

HEPATITIS B VIRUS;

EID: 0037184718     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(02)00253-6     Document Type: Article

References (27)

1. Berman J.J. Cell proliferation and the aetiology of hepatocellular carcinoma. J. Hepatol. 7:1988;305-309.
2. Britton R.S. Metal-induced hepatotoxicity. Semin. Liver Dis. 16:1996;3-12.
3. Bull P.C., Thomas G.R., Rommens J.M., Forbes J.R., Cox D.W. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet. 5:1993;327-337.
4. Cheng W.S., Govindarajan S., Redeker A.G. Hepatocellular carcinoma in a case of Wilson's disease. Liver. 12:1992;42-45.
5. Chen C.J., Yu M.W., Liaw Y.F. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 12:1997;S294-S308.
6. Christen S., Hagen T.M., Shigenaga M.K., Ames B.N. Chronic inflammation, mutation, and cancer. Parsonnet J., Hornig S. Microbes and Malignancy: Infection as a Cause of Cancer. 1999;35-88 Oxford Univ. Press, New York.
7. Di Bisceglie A.M., Rustgi V.K., Hoofnagle J.H., Dusheiko G.M., Lotze M.T. NIH conference. Hepatocellular carcinoma. Ann. Intern. Med. 108:1988;390-401.
8. Elmore L.W., et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc. Natl. Acad. Sci. USA. 94:1997;14707-14712.
9. Elzouki A.N., Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur. J. Gastroenterol. Hepatol. 8:1996;989-994.
10. Feder J.N., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13:1996;399-408.
11. Feitelson M.A., Zhu M., Duan L.X., London W.T. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 8:1993;1109-1117.
12. Hu K.Q., Yu C.H., Vierling J.M. Up-regulation of intercellular adhesion molecule 1 transcription by hepatitis B virus X protein. Proc. Natl. Acad. Sci. USA. 89:1992;11441-11445.
13. Huang W.S., Liao L.Y., Wang C.S., Chen P.H. Hepatocellular carcinoma presenting with acquired porphyria: a case report and review of the literature. Chang Keng I. Hsueh Tsa Chih. 22:1999;111-116.
14. Huo T.I., et al. Hepatitis B virus x mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene. 20:2001;3620-3628.
15. Hussain S.P., et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 60:2000;3333-3337.
16. Jia L., Wang X.W., Harris C.C. Hepatitis B virus X protein inhibits nucleotide excision repair. Int. J. Cancer. 80:1999;875-879.
17. Mahe Y., et al. Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor (B and CCAAT/enhancer-binding protein-like cis-elements. J. Biol. Chem. 266:1991;13759-13763.
18. Murakami T., Kim T., Nakamura H. Hepatitis, cirrhosis, and hepatoma. J. Magn. Reson. Imaging. 8:1998;346-358.
19. Niederau C., Fischer R., Sonnenberg A., Stremmel W., Trampisch H.J., Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N. Engl. J. Med. 313:1985;1256-1262.
20. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J. Clin. 49:(2):1999;33-64.
21. Pisani P., Parkin D.M., Bray F., Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer. 83:1999;18-29.
22. Powell L.W., Burt M.J., Halliday J.W., Jazwinska E.C. Hemochromatosis: genetics and pathogenesis. Semin. Liver Dis. 16:1996;55-63.
23. Ueda H., et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 9:1995;41-47.
24. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J.R., Harris C.C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci USA. 91:1994;2230-2234.
25. Wang X.W., et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 55:1995;6012-6016.
26. Wu C.G., et al. Distinctive gene expression profiles associated with hepatitis B virus x protein. Oncogene. 20:2001;3674-3682.
27. Zhou D.X., Taraboulos A., Ou J.H., Yen T.S. Activation of class I major histocompatibility complex gene expression by hepatitis B virus. J. Virol. 64:1990;4025-4028.